U.S. Biosimilars Market Estimations (2025 - 2035)
The U.S. biosimilars market covers biosimilar and interchangeable biosimilar medicines licensed by the FDA under section 351(k) and sold in the United States, including monoclonal antibody, insulin, G-CSF and other protein biosimilars, for immunology, oncology and supportive care, bone health, ophthalmology, diabetes and other uses, under Medicare Part B, Part D and commercial coverage.
📄Report ID:2525
|
📊Format: Databook
|
📅Published: 19 November 2026
|
⚡Delivery: Immediate